Advaxis Sinks On Delayed Disclosure Of Clinical Hold
This article was originally published in Scrip
Advaxis Inc. fell 25.8% in after-hours trading on Oct. 6 when the company said the US FDA placed a clinical hold on its investigational new drug (IND) application for axalimogene filolisbac (ADXS-HPV) – a disclosure that was made five days after Advaxis received word from the agency.
You may also be interested in...
Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.